Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche licenses Gilead's influenza candidates

Executive Summary

Hoffmann-La Roche has licensed the exclusive, worldwide rights to Gilead Sciences' neuraminidase inhibitors for the treatment of viral influenza, including GS-4104, in exchange for up to $50mm in upfront and milestone payments to Gilead.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Product or Technology Swap
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register